NEWS
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Daré Bioscience (NASDAQ: DARE) announced the publication of safety data from its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine.
The study, involving 1,357 sexual experiences, showed that the topical cream was safe and well-tolerated by women with female sexual arousal disorder (FSAD) and their partners. Notably, the cream did not produce common side effects associated with oral sildenafil, such as headache and flushing. This is likely due to the hundred-fold lower systemic exposure compared to oral dosing.
The study was designed to identify the most responsive patient population and appropriate patient-reported outcome measures for future Phase 3 trials.
Daré is currently in discussions with the FDA regarding the development program for Sildenafil Cream as an FSAD treatment.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
